标题
Selinexor in patients with advanced and recurrent endometrial cancer
作者
关键词
-
出版物
CURRENT PROBLEMS IN CANCER
Volume -, Issue -, Pages 100963
出版商
Elsevier BV
发表日期
2023-05-30
DOI
10.1016/j.currproblcancer.2023.100963
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CANCER-ASSOCIATED SF3B1 MUTATIONS CONFER A BRCA-LIKE CELLULAR PHENOTYPE AND SYNTHETIC LETHALITY TO PARP INHIBITORS
- (2022) Katrina M Lappin et al. CANCER RESEARCH
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- (2022) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
- (2022) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) A. Oaknin et al. ANNALS OF ONCOLOGY
- Endometrial carcinosarcoma
- (2022) Giorgio Bogani et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.
- (2021) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
- (2021) Nadeem R. Abu-Rustum et al. Journal of the National Comprehensive Cancer Network
- Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
- (2021) Hélène Marijon et al. Oncotarget
- Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
- (2021) Yoland Antill et al. Journal for ImmunoTherapy of Cancer
- DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
- (2021) Thibaud Prawitz et al. ADVANCES IN THERAPY
- Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
- (2021) Katelyn F. Handley et al. MOLECULAR CANCER THERAPEUTICS
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
- (2020) Nagesh Kalakonda et al. Lancet Haematology
- A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
- (2020) Maria M. Rubinstein et al. GYNECOLOGIC ONCOLOGY
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
- (2020) Nicole Concin et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies
- (2019) I.B. Vergote et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
- (2016) Ying Chen et al. CLINICAL CANCER RESEARCH
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
- (2016) Xuejiao Liu et al. Journal of Hematology & Oncology
- Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
- (2016) Manoj Garg et al. Oncotarget
- KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
- (2015) Giovanni Luca Gravina et al. BMC CANCER
- XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A
- (2015) T. Miyake et al. CLINICAL CANCER RESEARCH
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More